title: Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report.
abstract: BACKGROUND
  Oxaliplatin is a third-generation platinum compound with proven antitumor activity in the treatment of colorectal cancer. The occurrence of life-threating hemolitic uremic syndrome has been observed after oxaliplatin therapy. The kind of tumor and treatment modalities seem to influence the onset of hemolitic uremic syndrome.
  
  
  METHODS
  The clinical course of the case is reviewed and compared with reports of other similar cases in the literature.
  
  
  RESULTS
  We describe the development of hemolitic uremic syndrome as a result of prolonged oxaliplatin treatment of a colon cancer patient.
  
  
  CONCLUSIONS
  Although this rare event requires the concurrence of other unknown factors, it should be considered in a decision-making setting.
authors.affiliation: SSCVD Colorectal Cancer Unit, and 2SC Medical Oncology 1, AOU San Giovanni Battista, Turin, Italy. pracca@molinette.piemonte.it
authors.forename: Patrizia
authors.initials: P
authors.lastname: Racca
authors.forename: Rosella
authors.initials: R
authors.lastname: Spadi
authors.forename: Gianluca
authors.initials: G
authors.lastname: Fora
authors.forename: Laura
authors.initials: L
authors.lastname: Fanchini
authors.forename: Giuliana
authors.initials: G
authors.lastname: Ritorto
authors.forename: Laura
authors.initials: L
authors.lastname: Ferrari
authors.forename: Francesco
authors.initials: F
authors.lastname: Pinta
authors.forename: Patrizia
authors.initials: P
authors.lastname: Lista
authors.forename: Libero
authors.initials: L
authors.lastname: Ciuffreda
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004334:Drug Administration Schedule; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000139:chemically induced* / Q000628:therapy*; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin
chemical_list: D015415:Biomarkers; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin